Singularity Biomed Awarded NEOTEC Grant for REUMAP-PRO Project

We are proud to announce that Singularity Biomed has been awarded the prestigious NEOTEC grant by the CDTI (Centre for the Development of Industrial Technology). This funding marks a major milestone in our journey to revolutionize the management of Rheumatoid Arthritis (RA).

What is CDTI?

The CDTI (Centro para el Desarrollo Tecnológico Industrial) is a public business entity, answering to the Ministry of Science and Innovation, which fosters the technological development and innovation of Spanish companies. It is the entity that channels the funding and support applications for national and international R&D&I projects of Spanish companies.

The NEOTEC program specifically aims to support the creation and consolidation of technology-based companies, funding business projects that require the use of technologies or knowledge developed from research activity. It offers grants of up to 70% of the project budget, with a maximum amount of €250,000 per beneficiary.

Project REUMAP-PRO

This grant has been awarded for our project titled REUMAP-PRO, which focuses on applying our core technology to clinical practice.

• Project Code: SNEO-20201037
• Acronym: REUMAP-PRO
• Title: TECNOLOGÍA PARA EL SEGUIMIENTO DE PACIENTES CON ARTRITIS REUMATOIDE BASADA EN TERMOGRAFÍA INFRARROJA E INTELIGENCIA ARTIFICIAL: REUMAP-PRO (Technology for the Monitoring of Rheumatoid Arthritis Patients Based on Infrared Thermography and Artificial Intelligence)

Key Objectives

With the support of the NEOTEC grant, Singularity Biomed aims to achieve several critical goals:

1. Complete AI Development: Finalize the development of our machine learning models for the detection of arthritis activity using thermal images.
2. Develop Clinical App: Design and develop a specific mobile application for physicians. This tool will assist in the detection of inflammation during consultations, providing objective data in doubtful cases.
3. Business Growth: Accelerate our operational and commercial development to bring this technology to the market.

This support from CDTI validates our technological approach and provides the necessary resources to turn our scientific research into a tangible solution for doctors and patients.